Short-term antibiotics for MAC lung disease
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with MAC lung disease that shows a pattern called 'nodular bronchiectatic' on a CT scan.
- You have not taken any anti-MAC medications in the last 3 months.
- You agree to use birth control (if you could become pregnant or father a child) during the study and for 3 months after the last dose.
- Your blood and urine tests meet certain safety limits (for red blood cells, white cells, liver and kidney function, etc.).
- You do not have other serious lung conditions, an active cancer, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether cordyceps sinensis, a natural fungus, can help prevent a lung infection caused by MAC bacteria from returning. If you have finished treatment for MAC lung disease and your sputum tests are negative, you may be able to join.
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
This Phase 3 trial compares two antibiotics—clarithromycin and azithromycin—to treat lung infection caused by Mycobacterium avium complex (MAC). It may help by showing which antibiotic works better and is safer for people who need MAC treatment.
This trial tests whether inhaled hypertonic saline can improve symptoms and lung health in people with a specific lung infection called MAC. It targets adults with confirmed MAC infection and bronchiectasis who are not already on certain MAC medications.
Hear when a new Mycobacterium Avium Complex Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.